Published in Neurology on February 01, 1998
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol (2013) 4.16
fMRI evidence of compensatory mechanisms in older adults at genetic risk for Alzheimer disease. Neurology (2005) 3.22
Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. J Int Neuropsychol Soc (2006) 1.90
Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A (2010) 1.68
Verbal paired-associate learning by APOE genotype in non-demented older adults: fMRI evidence of a right hemispheric compensatory response. Neurobiol Aging (2006) 1.58
Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results From the National Institute of Mental Health's BIOCARD study. Neuropsychology (2005) 1.48
Decline in verbal memory during preclinical Alzheimer's disease: examination of the effect of APOE genotype. J Int Neuropsychol Soc (2002) 1.21
1H magnetic resonance spectroscopy, cognitive function, and apolipoprotein E genotype in normal aging, mild cognitive impairment and Alzheimer's disease. J Int Neuropsychol Soc (2002) 1.09
The apolipoprotein E gene, attention, and brain function. Neuropsychology (2002) 1.05
Mapping the effect of APOE epsilon4 on gray matter loss in Alzheimer's disease in vivo. Neuroimage (2009) 1.05
Sex differences in the association of the apolipoprotein E epsilon 4 allele with incidence of dementia, cognitive impairment, and decline. Neurobiol Aging (2010) 1.05
Normal genetic variation, cognition, and aging. Behav Cogn Neurosci Rev (2003) 1.04
Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease. Alzheimers Dement (Amst) (2015) 1.03
Hippocampal volumes are important predictors for memory function in elderly women. BMC Med Imaging (2009) 0.98
Neuropsychological performance in advanced age: influences of demographic factors and Apolipoprotein E: findings from the Cache County Memory Study. Clin Neuropsychol (2008) 0.97
Age-dependent loss of NGF signaling in the rat basal forebrain is due to disrupted MAPK activation. Neurosci Lett (2006) 0.96
Apolipoprotein E genotype and memory in the sixth decade of life. Neurology (2008) 0.95
The utility of placing recollection in opposition to familiarity in early discrimination of healthy aging and very mild dementia of the Alzheimer's type. Neuropsychology (2010) 0.92
Apolipoprotein E epsilon4 and impaired episodic memory in community-dwelling elderly people: a marked sex difference. The Hordaland Health Study. J Neurol Neurosurg Psychiatry (2006) 0.91
The influence of apolipoprotein E genotype on visuospatial attention dissipates after age 80. Neuropsychology (2009) 0.91
Cognitive discrepancies versus APOE genotype as predictors of cognitive decline in normal-functioning elderly individuals: a longitudinal study. Am J Geriatr Psychiatry (2008) 0.90
Asymmetry in auditory and spatial attention span in normal elderly genetically at risk for Alzheimer's disease. J Clin Exp Neuropsychol (2005) 0.90
Interactions of metals and Apolipoprotein E in Alzheimer's disease. Front Aging Neurosci (2014) 0.88
Neuropsychological deficits associated with Alzheimer's disease in the very-old: discrepancies in raw vs. standardized scores. J Int Neuropsychol Soc (2003) 0.86
Longitudinal change in working memory as a function of APOE genotype in midlife and old age. Scand J Psychol (2014) 0.84
An exploration of cognitive subgroups in Alzheimer's disease. J Int Neuropsychol Soc (2009) 0.82
APOE status and its association to learning and memory performance in middle aged and older Norwegians seeking assessment for memory deficits. Behav Brain Funct (2007) 0.80
Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults. Neuropsychologia (2015) 0.78
Frequency of the apolipoprotein E ε4 allele in a memory clinic cohort in Beijing: a naturalistic descriptive study. PLoS One (2014) 0.78
APOE and APOC1 gene polymorphisms are associated with cognitive impairment progression in Chinese patients with late-onset Alzheimer's disease. Neural Regen Res (2014) 0.77
Does the apolipoprotein E epsilon 4 genotype influence the expression of depression with cognitive impairment? Int J Geriatr Psychiatry (2009) 0.76
Age, family history, and memory and future risk for cognitive impairment. J Clin Exp Neuropsychol (2008) 0.76
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol (1997) 6.02
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Neuropathology of cognitively normal elderly. J Neuropathol Exp Neurol (2003) 5.17
Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology (2005) 5.02
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease. Neurology (1998) 3.90
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84
Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD. Neurology (2000) 3.84
Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology (2010) 3.83
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology (2009) 3.72
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology (2006) 3.60
The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol (1991) 3.45
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology (2004) 3.41
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology (2007) 3.24
Anterior temporal lobes and hippocampal formations: normative volumetric measurements from MR images in young adults. Radiology (1989) 3.12
The incidence of MCI differs by subtype and is higher in men: the Mayo Clinic Study of Aging. Neurology (2012) 3.01
Atrophy rates accelerate in amnestic mild cognitive impairment. Neurology (2007) 2.93
MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology (2003) 2.88
A short test of mental status: description and preliminary results. Mayo Clin Proc (1987) 2.85
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology (2009) 2.83
Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology (1999) 2.81
Mayo Clinic Alzheimer's Disease Patient Registry. Aging (Milano) (1990) 2.77
MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. Neurology (2008) 2.69
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology (2012) 2.68
Memory and MRI-based hippocampal volumes in aging and AD. Neurology (2000) 2.65
Head trauma as a risk factor for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.63
Risk of dementia among persons with diabetes mellitus: a population-based cohort study. Am J Epidemiol (1997) 2.60
Progressive aphasia secondary to Alzheimer disease vs FTLD pathology. Neurology (2008) 2.45
Aging, memory, and mild cognitive impairment. Int Psychogeriatr (1997) 2.45
1H MR spectroscopy in common dementias. Neurology (2004) 2.39
Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol (1991) 2.36
APOE modifies the association between Aβ load and cognition in cognitively normal older adults. Neurology (2011) 2.35
Post-lumbar puncture headaches: experience in 501 consecutive procedures. Neurology (1992) 2.30
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology (2000) 2.26
Alzheimer's disease and cumulative exposure to anesthesia: a case-control study. J Am Geriatr Soc (1994) 2.21
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Mayo's older Americans normative studies: category fluency norms. J Clin Exp Neuropsychol (1998) 2.18
DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology (2004) 2.12